vs
AdvanSix Inc.（ASIX）与科睿唯安（CLVT）财务数据对比。点击上方公司名可切换其他公司
科睿唯安的季度营收约是AdvanSix Inc.的1.6倍（$585.5M vs $359.9M），AdvanSix Inc.净利率更高（-0.8% vs -6.9%，领先6.1%），AdvanSix Inc.同比增速更快（9.4% vs -1.4%），科睿唯安自由现金流更多（$78.9M vs $36.1M），过去两年AdvanSix Inc.的营收复合增速更高（3.4% vs -5.1%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
ASIX vs CLVT — 直观对比
营收规模更大
CLVT
是对方的1.6倍
$359.9M
营收增速更快
ASIX
高出10.8%
-1.4%
净利率更高
ASIX
高出6.1%
-6.9%
自由现金流更多
CLVT
多$42.8M
$36.1M
两年增速更快
ASIX
近两年复合增速
-5.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $585.5M |
| 净利润 | $-2.8M | $-40.2M |
| 毛利率 | 7.6% | 67.2% |
| 营业利润率 | -0.7% | 5.2% |
| 净利率 | -0.8% | -6.9% |
| 营收同比 | 9.4% | -1.4% |
| 净利润同比 | -892.9% | 61.3% |
| 每股收益（稀释后） | $-0.11 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXCLVT
| Q1 26 | — | $585.5M | ||
| Q4 25 | $359.9M | $617.0M | ||
| Q3 25 | $374.5M | $623.1M | ||
| Q2 25 | $410.0M | $621.4M | ||
| Q1 25 | $377.8M | $593.7M | ||
| Q4 24 | $329.1M | $663.0M | ||
| Q3 24 | $398.2M | $622.2M | ||
| Q2 24 | $453.5M | $650.3M |
净利润ASIXCLVT
| Q1 26 | — | $-40.2M | ||
| Q4 25 | $-2.8M | $3.1M | ||
| Q3 25 | $-2.6M | $-28.3M | ||
| Q2 25 | $31.4M | $-72.0M | ||
| Q1 25 | $23.3M | $-103.9M | ||
| Q4 24 | $352.0K | $-191.8M | ||
| Q3 24 | $22.3M | $-65.6M | ||
| Q2 24 | $38.9M | $-304.3M |
毛利率ASIXCLVT
| Q1 26 | — | 67.2% | ||
| Q4 25 | 7.6% | 66.8% | ||
| Q3 25 | 6.8% | 65.0% | ||
| Q2 25 | 14.3% | 67.2% | ||
| Q1 25 | 14.2% | 65.1% | ||
| Q4 24 | 3.4% | 65.7% | ||
| Q3 24 | 14.4% | 66.2% | ||
| Q2 24 | 17.9% | 67.2% |
营业利润率ASIXCLVT
| Q1 26 | — | 5.2% | ||
| Q4 25 | -0.7% | 6.7% | ||
| Q3 25 | -0.9% | 7.1% | ||
| Q2 25 | 7.7% | 1.1% | ||
| Q1 25 | 7.7% | -3.5% | ||
| Q4 24 | -3.9% | -9.4% | ||
| Q3 24 | 7.5% | 3.5% | ||
| Q2 24 | 11.5% | -36.9% |
净利率ASIXCLVT
| Q1 26 | — | -6.9% | ||
| Q4 25 | -0.8% | 0.5% | ||
| Q3 25 | -0.7% | -4.5% | ||
| Q2 25 | 7.7% | -11.6% | ||
| Q1 25 | 6.2% | -17.5% | ||
| Q4 24 | 0.1% | -28.9% | ||
| Q3 24 | 5.6% | -10.5% | ||
| Q2 24 | 8.6% | -46.8% |
每股收益（稀释后）ASIXCLVT
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $-0.11 | $0.00 | ||
| Q3 25 | $-0.10 | $-0.04 | ||
| Q2 25 | $1.15 | $-0.11 | ||
| Q1 25 | $0.86 | $-0.15 | ||
| Q4 24 | $0.02 | $-0.27 | ||
| Q3 24 | $0.82 | $-0.09 | ||
| Q2 24 | $1.43 | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | — |
| 总债务越低越好 | — | $4.3B |
| 股东权益账面价值 | $815.2M | $4.8B |
| 总资产 | $1.7B | $10.9B |
| 负债/权益比越低杠杆越低 | — | 0.89× |
8季度趋势，按日历期对齐
现金及短期投资ASIXCLVT
| Q1 26 | — | — | ||
| Q4 25 | $19.8M | $329.2M | ||
| Q3 25 | $23.7M | $318.7M | ||
| Q2 25 | $18.4M | $362.6M | ||
| Q1 25 | $8.3M | $354.0M | ||
| Q4 24 | $19.6M | $295.2M | ||
| Q3 24 | $17.3M | $388.5M | ||
| Q2 24 | $12.1M | $376.4M |
总债务ASIXCLVT
| Q1 26 | — | $4.3B | ||
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $4.6B |
股东权益ASIXCLVT
| Q1 26 | — | $4.8B | ||
| Q4 25 | $815.2M | $4.8B | ||
| Q3 25 | $818.2M | $4.9B | ||
| Q2 25 | $823.7M | $5.0B | ||
| Q1 25 | $794.4M | $5.0B | ||
| Q4 24 | $774.6M | $5.1B | ||
| Q3 24 | $766.4M | $5.5B | ||
| Q2 24 | $746.6M | $5.6B |
总资产ASIXCLVT
| Q1 26 | — | $10.9B | ||
| Q4 25 | $1.7B | $11.1B | ||
| Q3 25 | $1.7B | $11.2B | ||
| Q2 25 | $1.6B | $11.4B | ||
| Q1 25 | $1.6B | $11.5B | ||
| Q4 24 | $1.6B | $11.5B | ||
| Q3 24 | $1.5B | $12.0B | ||
| Q2 24 | $1.5B | $12.1B |
负债/权益比ASIXCLVT
| Q1 26 | — | 0.89× | ||
| Q4 25 | — | 0.89× | ||
| Q3 25 | — | 0.90× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.83× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $134.7M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $78.9M |
| 自由现金流率自由现金流/营收 | 10.0% | 13.5% |
| 资本支出强度资本支出/营收 | 7.7% | 9.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | $333.9M |
8季度趋势，按日历期对齐
经营现金流ASIXCLVT
| Q1 26 | — | $134.7M | ||
| Q4 25 | $63.7M | $159.9M | ||
| Q3 25 | $26.6M | $181.1M | ||
| Q2 25 | $21.1M | $116.3M | ||
| Q1 25 | $11.4M | $171.2M | ||
| Q4 24 | $64.2M | $141.3M | ||
| Q3 24 | $57.3M | $202.9M | ||
| Q2 24 | $50.2M | $126.2M |
自由现金流ASIXCLVT
| Q1 26 | — | $78.9M | ||
| Q4 25 | $36.1M | $89.2M | ||
| Q3 25 | $66.0K | $115.5M | ||
| Q2 25 | $-7.2M | $50.3M | ||
| Q1 25 | $-22.6M | $110.3M | ||
| Q4 24 | $29.8M | $59.1M | ||
| Q3 24 | $26.8M | $126.3M | ||
| Q2 24 | $16.7M | $60.3M |
自由现金流率ASIXCLVT
| Q1 26 | — | 13.5% | ||
| Q4 25 | 10.0% | 14.5% | ||
| Q3 25 | 0.0% | 18.5% | ||
| Q2 25 | -1.7% | 8.1% | ||
| Q1 25 | -6.0% | 18.6% | ||
| Q4 24 | 9.1% | 8.9% | ||
| Q3 24 | 6.7% | 20.3% | ||
| Q2 24 | 3.7% | 9.3% |
资本支出强度ASIXCLVT
| Q1 26 | — | 9.5% | ||
| Q4 25 | 7.7% | 11.5% | ||
| Q3 25 | 7.1% | 10.5% | ||
| Q2 25 | 6.9% | 10.6% | ||
| Q1 25 | 9.0% | 10.3% | ||
| Q4 24 | 10.4% | 12.4% | ||
| Q3 24 | 7.7% | 12.3% | ||
| Q2 24 | 7.4% | 10.1% |
现金转化率ASIXCLVT
| Q1 26 | — | — | ||
| Q4 25 | — | 51.58× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
